ArticleESMO gastrointestinal oncology2025
Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination.
Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse-type gastric or gastroesophageal junctional cancers (DGC) often presents with peritoneal dissemination, leading to poor prognosis. This study assessed the efficacy of nivolumab-based therapies in patients with human epidermal growth factor receptor 2-negative DGC with peritoneal dissemination. Materials and methods: This retrospective analysis included patients with DGC treated between June 2017 and March 2024. One cohort ( Results: In the monotherapy cohort, 150 (81%) of 185 patients had peritoneal dissemination, which was significantly associated with worse progression-free survival (1.6 versus 2.5 months, Conclusions: First-line nivolumab plus chemotherapy demonstrated limited efficacy in human epidermal growth factor receptor 2-negative DGC with peritoneal dissemination but achieved a comparable OS to patients without peritoneal dissemination, supporting its potential as a first-line treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.